pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
TECVAYLI · news · pharmadog
← back to TECVAYLI
News mentioning TECVAYLI
15
stories
3d
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
3d
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
biospace
20d
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
20d
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
Sep 4, 26
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
biopharma dive
Sep 4, 26
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
biospace
Sep 3, 26
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
fiercebiotech
Aug 17, 26
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
Aug 17, 26
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
Jul 27, 26
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 16, 26
‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
fiercebiotech
Jun 26, 26
On second try, Acadia drug gets nod from European regulators
biopharma dive
May 6, 26
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
biopharma dive
Apr 29, 26
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
biopharma dive
